Cohance Lifesciences Limited
NSE: COHANCECohance Lifesciences Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.
Peers in Healthcare
Top 8 by market cap| Company | LTP | 30D | Market Cap | P/E | P/B | ROE % | Div Yld % |
|---|---|---|---|---|---|---|---|
| Cohance Lifesciences Limited(this stock) | ₹457.7 | ₹17,511 Cr | 170.0 | 4.5 | 3.8% | 0.00% | |
| Divi's Laboratories LimitedDIVISLAB | ₹9,087 | ₹2.41 L Cr | 83.0 | 14.5 | 16.2% | 0.33% | |
| Torrent Pharmaceuticals LimitedTORNTPHARM | ₹4,558.7 | ₹1.73 L Cr | 72.8 | 18.4 | 17.0% | 0.83% | |
| Laurus Labs LimitedLAURUSLABS | ₹2,069 | ₹1.12 L Cr | 101.8 | 21.0 | 17.7% | 0.12% | |
| Zydus Lifesciences LimitedZYDUSLIFE | ₹1,113.9 | ₹1.11 L Cr | 25.0 | 4.2 | 18.3% | 0.09% | |
| Apollo Hospitals Enterprise LimitedAPOLLOHOSP | ₹7,700 | ₹1.11 L Cr | 54.3 | 12.0 | 21.5% | 0.25% | |
| Aurobindo Pharma LimitedAUROPHARMA | ₹1,621.4 | ₹93,292 Cr | 26.1 | 2.6 | 9.9% | 0.00% | |
| Mankind Pharma LimitedMANKIND | ₹2,253.2 | ₹93,067 Cr | 46.0 | 5.8 | 12.4% | 0.00% | |
| Max Healthcare Institute LimitedMAXHEALTH | ₹830 | ₹80,785 Cr | 56.7 | 7.7 | 14.3% | 0.23% |
Quality Score
Durability · Valuation · Momentum — objective math, not adviceTechnical Indicators
Full analysis · objective math, not adviceTechnical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.
News & FilingsGoogle News + BSE
Suven Pharmaceuticals Share Price - Live NSE: COHANCE Stock Price & Chart
Upstox· 3d agoCohance Lifesciences (NSEI:COHANCE) Stock Forecast & Analyst Predictions
Simply Wall Street· 12 OctCOHANCE Stock Price and Chart — NSE:COHANCE
TradingView· 20 AugCohance's Umang Vohra says the worst is over; market looks for signs of recovery
Moneycontrol.com· 18 AugVolumes spurt at Cohance Lifesciences Ltd counter
Business Standard· 23 JunCohance Lifesciences share price surges 37% in two days on appointment of new CEO
Livemint· 28 Apr
News via Google News · Not verified by IPOpulse · Not investment advice
Community discussion(0)
Sign in to join the discussion.
Sign inNo comments yet — be the first to share your view.